Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. - Wikidata - wikimedia - TriplyDB

Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption.

Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption.

http://www.wikidata.org/entity/Q48198774

about

Astrocytic Toll-like receptor 3 is associated with ischemic preconditioning-induced protection against brain ischemia in rodents Antibodies as Mediators of Brain Pathology Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy Immune Regulation of Antibody Access to Neuronal Tissues The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.Antagonism of peripheral inflammation reduces the severity of status epilepticus.Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.Peripheral blood AKAP7 expression as an early marker for lymphocyte-mediated post-stroke blood brain barrier disruption Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages.Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury.Significance of marrow-derived nicotinamide adenine dinucleotide phosphate oxidase in experimental ischemic stroke.The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.Gene networks specific for innate immunity define post-traumatic stress disorder.Extracellular proteolytic pathophysiology in the neurovascular unit after stroke.Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells.Cytosolic Receptor Melanoma Differentiation-Associated Protein 5 Mediates Preconditioning-Induced Neuroprotection Against Cerebral Ischemic Injury.The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease Magnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosis Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases.Toll-like receptor signaling in endogenous neuroprotection and stroke.It's all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection.Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia.Does inflammation after stroke affect the developing brain differently than adult brain?Inflammation in adult and neonatal stroke.Toll-like receptor 3 agonist Poly I:C protects against simulated cerebral ischemia in vitro and in vivo.Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.Interferons in the central nervous system: a few instruments play many tunes.Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.The type I interferon response bridles rabies virus infection and reduces pathogenicity.Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia.Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain.Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion.Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients.Effect of interferon-β on neuroinflammation, brain injury and neurological outcome after experimental subarachnoid hemorrhage.Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats.Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.

P2860

Q21090615-63922786-8F0E-4B0B-9B6A-31AE7C01B694 Q26780374-075BD71A-E3ED-45BA-8B40-4BE5D2C9DA45 Q26782756-28065C51-657E-4126-A9DC-B6F09AA17BAC Q28733365-F620A5B3-6314-48FB-83D3-D6880CC23EBB Q30476952-BE320DB2-5CA0-4DE9-B152-8338C6FFAD45 Q30498265-3BEA6BD2-8BFF-4388-B3E3-5375A81B1843 Q33576939-BB746EFB-0970-4484-B577-7CF02735ED41 Q33683067-9366DDA0-C614-4663-85E0-6C122B376E88 Q33717808-F7590A0B-10C8-46DC-BD42-2CFED941629B Q34339353-1A3228DD-99CC-406B-82ED-14FC86986F9C Q35088789-75F9E4EC-E4CD-496E-BE17-3E116604CE95 Q35492103-C7F0E1CF-61ED-4BCA-954C-CA89EC3C7497 Q35621233-294F557F-A61B-4932-9AC0-BB3C3858C939 Q35962565-1D6312D2-011F-49F5-8009-085325BD0630 Q36048222-1D3BF805-42B5-4548-898D-C10D0EC901B9 Q36052713-0D0CE532-76B9-4C37-B244-589A114B03B8 Q36347457-B16807C4-B064-499B-AD92-689FA676D47B Q36423925-1A901558-14E5-4D25-9E2B-92924DCDCFE9 Q36444483-A22CBA03-370D-4352-B9FB-6A7E8943FB24 Q36537921-1BED5D73-4847-4A47-BEF9-457CA737AF20 Q36839991-81912EBC-BBB2-48ED-BD92-8B5BDD176883 Q36987436-4AD765DB-A061-4C6E-8FE6-BF3756E2D2A6 Q37171364-022F0BB5-F904-4A3C-A0A1-931FC05581E7 Q37259848-1FD0F0DD-3D64-4682-8F10-12825191A00A Q37312320-179CDF82-6CE9-44FE-8F30-452F550C368B Q37466730-E7171F36-DBD8-4282-BFD8-F7584B29C359 Q37714376-96582518-A508-477B-8093-A06B52B49E8F Q37728693-4E6EA6AE-3683-49E3-BF49-C3156E550CCD Q38004932-35B52D98-7E7B-4857-876D-24FB83BF0029 Q38192651-CC365263-8FFB-4FBA-B33C-636DEB7CAF71 Q38931847-5FA20686-52F9-4FC0-A650-EBE80B32CE2C Q39497376-944E54A2-FD96-4D21-832B-1E9156DF7809 Q40020998-29F70E3E-53B8-4F5C-AF4D-694B3D8E4222 Q42475527-329454C5-E4CB-42E8-8719-2AA075EF0939 Q42795549-5823F42E-6353-48E4-A74C-8418E9832EB3 Q43181265-3238E7A3-F08D-48B7-9808-D706E4FDE6CB Q43185918-8CD823DC-3B3D-42FE-AC8C-D0268CA6645F Q47999033-0BB7F4A0-81CD-47B4-8125-7C572915695A Q48314697-04700BC4-2F04-4D67-9B45-1040075650D8 Q48785648-1AFD9874-DEB5-47BF-9D80-B13B084D494F

P2860

Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption.

http://www.wikidata.org/entity/Q48198774

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Interferon-beta prevents cytok ...... lood-brain barrier disruption.

@en

Interferon-beta prevents cytok ...... lood-brain barrier disruption.

@nl

type

label

Interferon-beta prevents cytok ...... lood-brain barrier disruption.

@en

Interferon-beta prevents cytok ...... lood-brain barrier disruption.

@nl

prefLabel

Interferon-beta prevents cytok ...... lood-brain barrier disruption.

@en

Interferon-beta prevents cytok ...... lood-brain barrier disruption.

@nl

P1433

Q48198774-D2D48137-C169-4443-94D6-3519739502BA

P1476

Q48198774-258163CE-5209-437B-8993-F8543F4DD86C

P2093

Q48198774-160EF914-BB5E-4B70-84C3-E134E42EB26A

Q48198774-26D06A5C-5758-4942-8941-FAAE1580BA72

Q48198774-48FF6C85-B84C-4DC7-9232-010093C49290

Q48198774-4950DC30-D22D-4149-BDD9-4E603D6FA8C5

Q48198774-660BBD42-0E37-4FC3-9507-CFDF234CF891

P2860

Q48198774-03F44E59-5227-4A6B-9641-E9250121AC2D

Q48198774-17C31B18-E069-4530-ADEF-75D03E64B58E

Q48198774-1E352E97-4629-4EBC-A9DB-C5087CFC0E38

Q48198774-2545E196-E858-4E49-A25D-30C835D9376B

Q48198774-2CF20249-E032-4CB6-835F-F540C8E3CF0B

Q48198774-3B3FFE59-C804-488D-B6A8-869E57EEA97B

Q48198774-41476BD2-569D-480C-B1F3-B217E35E5BC2

Q48198774-48F0FBE7-45AF-4CA2-A046-4B93B7B222F4

Q48198774-4BEFEB85-3F71-4EB4-A56C-FB739E935D11

Q48198774-4ED9801B-C67E-403E-AACB-5491DF491534

P2888

Q48198774-92D67700-F553-404D-B447-56E8BF2FC016

P304

Q48198774-8626FD00-E849-4871-8329-861EB81ACC5E

P31

Q48198774-2FF07B17-F5FF-49E3-974D-8636F86F3012

P356

Q48198774-0EB41F95-DDC0-409D-BF2F-9B4AC7C7331B

P433

Q48198774-B1FA7BA7-42A5-43B4-B66B-42FEAAC99B51

P478

Q48198774-1C3532C4-6238-4764-9F29-A002790539D0

P50

Q48198774-81CAB7B8-0D94-4928-B8D7-EA09C2F5CB37

Q48198774-BFDF2C96-F23C-4F03-958F-B95044AACF6C

Q48198774-E0CE9ACA-9A39-468C-BA46-4458198C0BFD

P577

Q48198774-ECADE343-3199-47E5-A513-AE33F7AF9CFA

P5875

Q48198774-F90572AD-B180-4748-A534-A6C4EF044CB5

P6179

Q48198774-1DF26DBA-B70B-40F1-9542-4F45AF77EED5

P698

Q48198774-F6D6ED3D-578B-40B8-A3A8-887AE7DBAECE

P921

Q48198774-245ADE68-8E1C-451F-B3CD-7E76FE2E293A

P356

01.WCB.0000080701.47016.24

P1433

Journal of Cerebral Blood Flow & Metabolism

P1476

Interferon-beta prevents cytok ...... blood-brain barrier disruption

@en

P2093

Christien D Dijkstra

http://www.w3.org/2001/XMLSchema#string

Peter H van der Meide

http://www.w3.org/2001/XMLSchema#string

Peter R Bär

http://www.w3.org/2001/XMLSchema#string

Sarah Floris

http://www.w3.org/2001/XMLSchema#string

Wouter B Veldhuis

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

Single-shot diffusion trace (1)H NMR spectroscopy.

Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia.

Inflammatory mediators and stroke: new opportunities for novel therapeutics.

Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.

Interleukin 1 in the brain: biology, pathology and therapeutic target.

Cerebral ischemia and inflammation.

Interleukin-8 and the chemokine family.

Involvement of inflammatory cytokines in central nervous system injury.

Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system.

P2888

01.wcb.0000080701.47016.24

P304

1060-1069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.WCB.0000080701.47016.24

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Catharina M P Vos

Helga E de Vries

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5257154

http://www.w3.org/2001/XMLSchema#string

P6179

1005203014

http://www.w3.org/2001/XMLSchema#string

P698

12973022

http://www.w3.org/2001/XMLSchema#string

P921

blood–brain barrier